Breakthroughs in Leveraging Biomarkers for Oncology 2017 - Accelerating Solutions for Cancer Diagnostics and Therapeutics

News provided by

Oct 17, 2017, 15:30 ET

DUBLIN, October 17, 2017 /PRNewswire/ --

The "Breakthroughs in Leveraging Biomarkers for Oncology" report has been added to Research and Markets' offering.

Predictive biomarkers are used to provide the best treatment indication with the greater probability of response to a certain specific chemotherapeutic agent, also considering treatment-related side effects. Prognostic biomarkers are used to identify patients with different clinical outcomes associated with somatic mutations, alterations in DNA methylation, germline polymorphisms, serum cytokine levels, expression of micro-RNA (miRNA) as well as circulating tumor cells (CTCs) in blood.

Therefore, the precise identification of highly specific and sensitive biomarkers corresponding to certain clinical outcomes or antitumor effects constitutes one of the most crucial tasks in cancer research and treatment.

This research service depicts how biomarkers research has remarkably progressed in oncology and accelerates novel therapeutics discovery and development. In fact, recent biomarker research has outstandingly progressed and assisted early drug discovery and development by providing novel molecular-targeting agents in the field of oncology.

Key Topics Covered:

1. Executive Summary
1.1 Research Scope - Breakthroughs in Leveraging Biomarkers
1.2 Research Focus - New Trends in Immuno-Oncology Biomarkers
1.3 Research Framework - Predictive and Prognostic Biomarkers
1.4 Research Methodology
1.5 Research Methodology - The Five Steps Toward Success
1.6 Key Facts and Findings - The Global Picture in Numbers

2. Industry Features and Future Concepts
2.1 Key Elements of Analysis - The Ideal Biomarker' Concept
2.2 Oncology Biomarkers Value Chain - Overall Landscape
2.3 Key Elements of Analysis: Oncology Accelerated Pathway
2.4 Key Elements of Analysis - Biomarker Stratification
2.5 Key Elements of Analysis - Business and Processes
2.6 Key Elements of Analysis - Emerging Business Models
2.7 Value Chain Interactive Model and Elements of Interaction
2.8 Product Development and Commercialization
2.9 Product Development and Commercialization - Time to Market

3. Technology Snapshot and Trends
3.1 Emerging Technological Landscape for Oncology Biomarkers
3.2 Proteomic Markers Expected to Transform the Future of Precision Oncology
3.3 Nucleic Acid Biomarkers Likely to Dominate Screening and Predictive Applications in Clinical Oncology
3.4 Emerging Metabolomic Profiling Assays May Facilitate Enhanced Cancer Diagnosis and Prognosis

4. Emerging Innovation Landscape
4.1 Redefining Oncology Diagnostics Through Comprehensive Biomarkers Assays
4.2 Proteomic Markers for Precision Oncology Applications
4.3 Recent Advances in Genomic Oncology Biomarker Technologies
4.4 Precision Oncology Likely to be an Important Emerging Trend

5. Analysis of Biomarkers by Cancer Indications
5.1 Molecular Markers Impact Diagnosis and Management of Key Cancer Indications
5.2 Diagnosis and Efficacy are the Key Application Areas for Breast Cancer Biomarkers
5.3 Genomic and Biochemical Markers Lead Diagnostic and Efficacy Applications in the Lung Cancer Industry
5.4 Colorectal Cancer Markers Aid Diagnostic and Prognostic Applications
5.5 Biomarkers for Prostate Cancer Lead Diagnostic and Efficacy Applications
5.6 Emerging Cervical Cancer Biomarkers Likely to be Useful as Therapeutic Targets

6. Market Potential and Intellectual Property
6.1 Oncology Biomarkers Impact Global Cancer Diagnostics Market
6.2 North America Leads the Global Oncology Biomarkers Market
6.3 Lung and Breast Cancer Biomarkers Present Largest Global Market Opportunities
6.4 Defining Patent Research Scope and Search Concepts for Oncology Biomarkers
6.5 Roche and Immatics Lead Patent Landscape for Oncology Biomarkers
6.6 US Dominates the Global Blockchain Patent Portfolio Distribution for Oncology Biomarkers
6.7 Rising Patent Publication Trend for ancer Biomarkers

7. Growth Opportunities and Companies to Action
7.1 Growth Opportunities - Leveraging Proteomic Markers for Companion Diagnostic Platforms
7.2 Growth Opportunities - Nucleic Acid Biomarkers Fuel Precision Oncology Advancement
7.3 Growth Opportunities - Metabolomic Markers Likely to be of Growing Importance in Cancer Therapy
7.4 Strategic Imperatives for Success and Growth

For more information about this report visit https://www.researchandmarkets.com/research/wrbq8x/breakthroughs_in

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets